White Paper

Clinical Road Map To Success For Over-encapsulation

By Richard Shannon, Vice President of Business Development, Almac Clinical Services

Clinical Road Map To Success For Over-encapsulation

Download Complete White Paper

A recent analysis conducted by the Tufts Center for the study of Drug Development1 estimated that the average cost to develop and gain marketing approval for a new drug is in excess of $2.55 billion (based upon out of pocket and time costs), so the need to prove superior efficacy and safety when compared to an already marketed product is of critical importance. When developing protocol designs, blinding or masking of clinical supplies is an integral part of many studies. This can help remove both investigator and patient bias due to the visibility of the marketed product, and can limit any potential placebo effect. One of the extensively used mechanisms available to sponsor companies to promote blinding is the over-encapsulation of tablets or capsules.

Over-encapsulation is a widely accepted mechanism used throughout the clinical supplies industry, and while the process itself may appear relatively straightforward, packaging for clinical supplies is a complex process that is strictly controlled by Good Manufacturing Practice (GMP). The principle of over-encapsulation is simply the addition of a product or products to a hard gelatine capsule (although use of non-gelatine capsules is increasing), which may or may not be backfilled with an inactive bulking agent or excipient. This process can be used for comparator products, Investigational Medicinal Products (IMPs) and/or placebos, providing an output of visually identical capsules for each product or strength, thus maintaining the blind and removing any potential bias.

This article will review the mechanisms and techniques currently available to promote successful over-encapsulation. However, there are a number of key GMP challenges that need to be addressed in order to ensure product and study result integrity. Annex 13 defines the data that should be available (for example stability, comparative dissolution and bioavailability) to show that there has been no significant quality change within the product, and also clarifies how expiry dates should be justified and assigned2. In addition, there is a need to tightly control and scrutinize the manufacturing process, not only to ensure that the product is blinded appropriately, but also to allow rapid identification of the product in the case of any possible emergency2. Allied with this is the visible branding of commercial products either via the placement of product/sponsor logos directly onto products, or patented shapes/designs, meaning that encapsulation is not as easy as it may initially appear.

1 Tufts CSDD Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published, 10 March 2016
2 Eudralex, The Rules Governing Medicinal Products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice, Medicinal Products of Human and Veterinary Use, Annex 13, Investigational Medicinal Products

Download Almac’s White Paper to understand the mechanisms and techniques currently available to promote successful over-encapsulation.